I am right with you. Sorrento has a High potenrial but is only selling one product that might pay the waterbill and cable. Hard cold facts is that they have 133 pattents of which 36 have been granted since 2013-12-05 and several added companies adding to overhead. Lots of programs ( 22) in 4 portfolios of which none are in production adding to cashflow. Maybe 100 million shares waiting to be added to the 260M being played with. That is where they are Today. 2021 is the year for Sorrento with 2022 and 2023 adding value...IF they receive FDA approval. There are thousands of programs that have been put aside due to COVID and will flood the zone once COVID is on the downside but the window is closing and Sorrento has to get approvels by mid year on a meaningful number of COVID programs or they could be in for a long dry spell. I believe STI 2020 COVI-AMG™, Covi-STIX, COVI-DROPS STI 2099 will be approved H1 2021 and a good shot for ABIVERTINIB STI 5656 also. I do not plan on selling soon but will over a period of years depending on tax code...not until late 2021 or 2022. It would be nice to know what the plan for SALICYN-30 Anti-viral – STI 2030 is. The company has value but the marketplace determines that value and quite frankly the marketplace by this time next year...
Market Data 
Markets 
AI
